| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Entry into a Material Definitive Agreement
On November 6, 2026, Alkermes, Inc. and Alkermes Pharma Ireland Limited (together, “Alkermes”), two wholly-owned indirect subsidiaries of Alkermes plc (the “Company”), entered into a Confidential Settlement and License Agreement (the “Se... |
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition
— GAAP Net Income of $16.3 Million and Adjusted EBITDA of $120.1 Million — |
| 21 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) |
| 16 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
DUBLIN, Sept. 16, 2026 — Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the company’s Board of Directors (the Board). Ms. Whitaker is a seasoned biopharmaceutical executive... |
| 12 Aug 2026 |
8-K: Entry into a Material Definitive Agreement
This Amendment No. 1 to Credit Agreement, dated as of August 12, 2026 (this “Amendment”), to the Credit Agreement, dated as of February 12, 2026 (as amended, restated, supplemented or otherwise modified from time to time prior to the dat... |
| 28 Jul 2026 |
8-K: Results of Operations and Financial Condition
— GAAP Net Income of $0.5 Million and Adjusted EBITDA of $139.2 Million — |
| 08 Jul 2026 |
8-K: Termination of a Material Definitive Agreement
On July 6, 2026, Alkermes plc (the “Company”) and Amneal Pharmaceuticals LLC (“Amneal”) terminated the previously disclosed Authorized Generic Product Supply Agreement entered into on September 9, 2025 (the “Agreement”). Capitalized term... |
| 15 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
DUBLIN, June 15, 2026 -- Alkermes plc (Nasdaq: ALKS) today announced that alixorexton, a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy type 1 (NT1), narcolepsy typ... |
| 20 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
The name of the plan is the Alkermes plc 2018 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and consultants of Alkermes plc, an Irish publ... |
| 12 May 2026 |
8-K: Regulation FD Disclosure; Other Events
Alkermes Announces Positive Topline Results From REVITALYZSM Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition
— First Quarter Revenues of $392.9 Million; GAAP Net Loss of $66.5 Million and Adjusted EBITDA of $80.3 Million — |
| 25 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
— Richard Pops to Retire from Role of Chief Executive Officer Following Distinguished 35-year Career with Alkermes — |
| 25 Feb 2026 |
8-K: Results of Operations and Financial Condition
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026 |
| 12 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +3 more
NOTICE: Under the Credit Reporting Act 2013 lenders are required to provide personal and credit information for credit applications and credit agreements of €500 and above to the Central Credit Register. This information will be held on ... |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Alkermes 2026: Driving Profitable Growth in Neuroscience and Leading Orexin Innovation January 2026 Exhibit 99.1 |
| 06 Jan 2026 |
8-K: Regulation FD Disclosure; Other Events
DUBLIN, Jan. 6, 2026 -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1), based on phase... |
| 19 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
Form of U.S. Tax Certificate (Foreign Lenders That Are Not Partnerships) |
| 12 Nov 2025 |
8-K: Regulation FD Disclosure; Other Events
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2 |
| 28 Oct 2025 |
8-K: Results of Operations and Financial Condition
— GAAP Net Income of $82.8 Million and Diluted GAAP Earnings per Share of $0.49 — |
| 22 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
Form of U.S. Tax Certificate (Foreign Lenders That Are Not Partnerships) |
Loading...